The 15th annual BIO Asia International Conference is an exclusive partnering forum that brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market.

Who Should Attend:
- Drug development and discovery companies
- Biopharmaceutical companies
- Medical technology companies
- Universities and institutes
- Intellectual property and legal organizations
- Investors and financial services providers
- Bio-clusters and incubators
- Government and public support agencies

Highlights/Statistics from Prior Year:
Expanded programming featured leading experts from the organizations at the forefront of biopharma on the Pacific Rim to support international market expansion and cross-border research collaboration. Topics explored emerging deal-making trends, adapting clinical trial strategies across regulatory regimes, and shifts in Asian investment patterns among different therapeutic development specialties.

- **370** Delegates
- **27** Countries
- **1,200+** BIO One-on-One Partnering™ meetings
- **230+** Companies represented
- **35** Innovative companies from around the world presenting their story

Audience Demographics

- **Biotech** 38%
- **Large Pharma** 34%
- **Other** 18%

Presenting Companies: Breakdown by Therapeutic Area

- **Oncology** 29%
- **Gene/Cell Therapy** 7%
- **Vaccines** 5%
- **Infectious Diseases** 5%
- **Regenerative Medicine** 4%
- **Orphan/Rare Diseases** 4%
- **Platform for Therapeutics** 4%
- **Multiple Therapeutics** 4%
- **Multiline Global Biopharma** 4%
- **Other 3%**
- **Drug Delivery 3%**
- **Gastrointestinal 3%**
- **Cardiovascular 3%**
- **Respiratory 1%**
- **Ophthalmology 1%**
- **Metabolic Diseases 1%**
- **Immunology 1%**
- **Diagnostics 1%**

Attendance by Region

- **Asia (outside Japan)** 17%
- **Europe** 19%
- **Japan** 28%
- **United States** 31%
Past Speakers

Seishi Baba
Parliamentary Vice-Minister of Health, Labor and Welfare, Japan

Philippe Fauchet
OBE, President & Representative Director, GlaxoSmithKline K.K.

David Meeker, MD
Executive Vice President, Sanofi and Head of Sanofi Genzyme

Jingsong Wang, MD, PhD
Chief Executive Officer, Harbour BioMed

Subesh Williams
Senior Vice President, Global Corporate Development, GlaxoSmithKline plc

Opportunity for organizations to deliver company presentations, providing increased visibility in front of a global audience of biotech and pharmaceutical companies, all interested in cross-border business development alliances.

BIO One-on-One Partnering enables attendees to: search company and investor profiles, drug assets, products, and services in the biopharma industry; evaluate potential collaborations and funding opportunities with participating companies; communicate directly with prospective investors and senior business and scientific management from the U.S., Japan, Europe, and the Asia Pacific region; and pre-schedule private, 30 minute One-on-One meetings to be conducted onsite.

Panel discussions will increase your understanding of, and interaction with, the Japanese biotech market, the political landscape in Japan, and its impact on this important industry sector.

Network with government leaders, peers, investors, and potential partners attending the conference and our exclusive welcome reception.

Registration Packages and Fees

<table>
<thead>
<tr>
<th>Registration Categories</th>
<th>Rate (in JPY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investors</td>
<td>103,000</td>
</tr>
<tr>
<td>Discovery Company</td>
<td>50,000</td>
</tr>
<tr>
<td>Government / Academic / Non-Profit</td>
<td>50,000</td>
</tr>
<tr>
<td>Biotech / Pharma Company</td>
<td>120,000</td>
</tr>
<tr>
<td>Additional Attendee</td>
<td>75,000</td>
</tr>
</tbody>
</table>

Apply to join the 2018 Committee by emailing your interest to nsagherian@bio.org.